Vital Farms Shows Stabilization but Recovery Remains Unproven

What happened

Vital Farms reported a weak Q2 with revenue down 10% year-over-year, gross margin compressing to 6.6%, and meaningful cash burn, yet the company beat revenue expectations and reaffirmed its full-year guidance. Management attributes the margin collapse to ERP transition costs and supply chain disruptions, expecting gross margin to recover to roughly 30% by Q4, but concedes that structural changes make a return to historical 35-40% margins unlikely. This follows the December 2025 revenue guidance reset linked to ERP-driven ordering disruptions, which has been a key overhang alongside an unremediated material weakness in revenue-process controls disclosed in the last 10-Q. Early signs of stabilization, including narrowing price gaps and improving supply, suggest the worst may be over, but they are not yet conclusive proof of a durable recovery. The analyst maintains a wait-and-see stance, needing more evidence of normalized ordering and control remediation before turning constructive.

Implication

The reaffirmed guidance and expected Q4 margin recovery suggest the ERP disruption is fading, but the low starting point implies the company will operate with structurally lower margins than before. Investors should monitor Q3 and Q4 gross margin trajectory, the FY2025 10-K for control remediation status, and retailer ordering patterns for signs of normalization. Until then, the stock remains fairly valued, with an attractive entry near $24 and trim above $33, but the re-assessment window should extend to after Q3 results or the 10-K filing. The bull case requires execution on margin recovery; any slip could push the stock toward the bear scenario of $21.

Thesis delta

The thesis is unchanged in direction but gains nuance: Q2 results confirm the recovery is starting, as management anticipated, but the severity of margin compression and cash burn underscores that the turnaround is still fragile. The probability of the base case has modestly increased as the company met expectations, yet the risk of structural margin reset remains a key concern. We continue to wait for more proof before adjusting the WAIT rating.